 Connection
Mark Gerich to Immunosuppressive Agents
This is a "connection" page, showing publications Mark Gerich has written about Immunosuppressive Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.397 |
|
|
|
-
Gerich M, Yoon J, Vasiliauskas E. Editorial: is thalidomide a good option for patients with refractory Crohn's disease? Authors' reply. Aliment Pharmacol Ther. 2015 Apr; 41(8):786.
Score: 0.382
-
Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther. 2015 Mar; 41(5):429-37.
Score: 0.374
-
Gerich ME, Pardi DS, Bruining DH, Kammer PP, Becker BD, Tremaine WT. Tacrolimus salvage in anti-tumor necrosis factor antibody treatment-refractory Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1107-11.
Score: 0.334
-
Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis. 2010 Nov; 4(5):546-52.
Score: 0.273
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.034
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|